Herman Lawrence, Atri Alireza, Salloway Stephen
Dean, Professor and Program Director, Physician Assistant Studies, Gardner-Webb University, College of Health Sciences, Boiling Springs, North Carolina.
Ray Dolby Endowed Chair in Brain Health Research, Director, Research & Education, Ray Dolby Brain Health Center, California Pacific Medical Center (CPMC), Senior Scientist, CPMC Research Institute, San Francisco, California; Visiting Scientist, Neurology, Center for Brain/Mind Medicine, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Am J Med. 2017 Jun;130(6):756. doi: 10.1016/j.amjmed.2017.04.001. Epub 2017 Apr 25.
The field of Alzheimer's disease (AD) is undergoing a profound and rapid change: clinical trials have been redesigned to focus on individuals in the earliest stages of the disease and are including more sensitive measurement tools to better capture changes in cognition and other outcomes. (Online access: http://courses.elseviercme.com/adwebcast/674http://courses.elseviercme.com/alzheimer/593e). Trial participants undergo PET imaging for amyloid load as a hallmark for dementia, as well as genetic testing to determine likelihood of disease progression and response to therapeutic intervention. Large national and international registries have been established to capture those at risk and to follow their development of cognitive changes longitudinally. Understanding that the disease process starts at least a decade or more before the onset of symptoms has prompted the development of therapeutic interventions acting very early in the disease cascade. For all these reasons, recognizing and diagnosing AD early offers affected individuals and their caregivers the best chance for care planning, access to available symptomatic treatment and community resources, as well as involvement with clinical trials and access to new therapies when they become available. Primary care clinicians play a pivotal role in the early recognition of cognitive impairment in their patients.
阿尔茨海默病(AD)领域正在经历深刻而迅速的变革:临床试验已重新设计,聚焦于疾病最早期的个体,并纳入了更敏感的测量工具,以更好地捕捉认知及其他结果的变化。(在线访问:http://courses.elseviercme.com/adwebcast/674http://courses.elseviercme.com/alzheimer/593e)。试验参与者要接受正电子发射断层扫描(PET)成像以检测淀粉样蛋白负荷,作为痴呆的一个标志,还要进行基因检测,以确定疾病进展的可能性以及对治疗干预的反应。已经建立了大型的国家和国际登记处,以记录有风险的人群,并纵向跟踪他们认知变化的发展情况。认识到疾病过程在症状出现前至少十年或更早就已开始,促使人们开发在疾病级联反应早期就发挥作用的治疗干预措施。出于所有这些原因,早期识别和诊断AD为受影响的个体及其护理人员提供了最佳机会,以便进行护理规划、获得现有的对症治疗和社区资源,以及参与临床试验并在新疗法可用时获得这些疗法。初级保健临床医生在早期识别患者的认知障碍方面发挥着关键作用。